Desensitization: Overcoming the Immunologic Barriers to Transplantation - Wikidata - wikimedia - TriplyDB

Desensitization: Overcoming the Immunologic Barriers to Transplantation

Desensitization: Overcoming the Immunologic Barriers to Transplantation

http://www.wikidata.org/entity/Q30397952

about

HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs Desensitisation strategies in high-risk children before kidney transplantation.

P2860

Q33786811-19218EF9-4980-4C94-85EC-787A93975E71 Q47563660-8BBF4325-C0D7-46C1-B8B1-A81E6BB24289

P2860

Desensitization: Overcoming the Immunologic Barriers to Transplantation

http://www.wikidata.org/entity/Q30397952

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Desensitization: Overcoming the Immunologic Barriers to Transplantation

@ast

Desensitization: Overcoming the Immunologic Barriers to Transplantation

@en

type

label

Desensitization: Overcoming the Immunologic Barriers to Transplantation

@ast

Desensitization: Overcoming the Immunologic Barriers to Transplantation

@en

prefLabel

Desensitization: Overcoming the Immunologic Barriers to Transplantation

@ast

Desensitization: Overcoming the Immunologic Barriers to Transplantation

@en

P1433

Q30397952-957FC872-B443-42D7-BD23-2F2E1D02AF29

P1476

Q30397952-5898BECF-0D3F-458B-BB3E-CD59C72BCB02

P2093

Q30397952-182737AE-AC65-463E-A979-AAAD7E5EFF47

Q30397952-53AD9FF7-0AB5-4319-9802-0E175AB72FCC

Q30397952-7DE3684B-DA25-4A74-84FC-B8402AA9C69C

Q30397952-97997E40-C0F7-48DD-8B49-99C31BB44C7A

P275

Q30397952-AC22D9D6-1D0F-4F10-9BA5-9E6148349A20

P2860

Q30397952-00753CC6-DED3-4EE5-A6EC-B2E438C97107

Q30397952-0EE949F3-F3C1-4F14-AFDF-162875448CC4

Q30397952-10183733-06A0-46CF-8611-4D98ACC9E98C

Q30397952-1069F622-8344-4B05-8818-65A3FCB6B501

Q30397952-126380C8-0514-4FC3-810C-70E1E931E872

Q30397952-13826478-F7DB-45BF-96AD-1D63987844BA

Q30397952-248C6BEF-6659-40C0-923E-2B0B00D78023

Q30397952-27DA57BA-5F8A-45BE-A85F-739F88FBC21B

Q30397952-2AEC6FC3-3829-4614-8484-B5957D9E05B8

Q30397952-2F078908-09AA-424C-9068-7B061FC37E2A

P304

Q30397952-1FB4568F-1756-407F-9B1B-9D9DF2158F55

P31

Q30397952-031D63F3-916B-4CBF-AAF1-65D2BBC551ED

Q30397952-44F4871D-743E-4CB0-A18C-9E090224A992

P356

Q30397952-43CD9F50-6738-47F9-B17B-4B551F5AF245

P478

Q30397952-0278CE7E-5BAC-4C91-93B4-8A1892957E10

P50

Q30397952-77D1D695-FE14-4D71-8130-C36ED267FE70

Q30397952-89A131CB-1B9E-46C3-A581-80A69B171D9D

P5008

Q30397952-065B981C-D936-44BD-966E-F12F6134B83D

P577

Q30397952-723EC050-85FB-4C53-9DB6-1F4DA38663CE

P698

Q30397952-C48AFC22-E367-4083-B93C-5D9EE23801D4

P921

Q30397952-232FEE08-2AFF-46D0-9876-620DEE76E137

Q30397952-2A22A631-EFD4-4005-A919-39F77FC7BFFD

Q30397952-A6ED4371-BA26-4FC2-B8FE-1D342592F091

Q30397952-C018A341-903D-4693-9B86-C9802E468970

Q30397952-E1E3BA5F-1AB1-4675-BD43-14B59B5D2C1B

P932

Q30397952-B8B5902B-7439-4E14-8CE6-B9AECB253B9F

P356

P1433

Journal of Immunology Research

P1476

Desensitization: Overcoming the Immunologic Barriers to Transplantation

@en

P2093

Alice Peng

http://www.w3.org/2001/XMLSchema#string

Ashley Vo

http://www.w3.org/2001/XMLSchema#string

Jua Choi

http://www.w3.org/2001/XMLSchema#string

Stanley C Jordan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody

IdeS: a bacterial proteolytic enzyme with therapeutic potential

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.

U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.

Intravenous immunoglobulin as clinical immune-modulating therapy.

Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.

Bortezomib in multiple myeloma: systematic review and clinical considerations.

Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation

The complement system

Belimumab: review of use in systemic lupus erythematosus.

P304

6804678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2017/6804678

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2017-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28127571

http://www.w3.org/2001/XMLSchema#string

P921

preventive health services

biomedical investigative technique

chronic kidney disease

P932

5239985

http://www.w3.org/2001/XMLSchema#string